慶應義塾研究者情報データベース

総合紹介 【 表示 ／ 非表示 】

総合紹介 【 表示 ／ 非表示 】

経歴 【 表示 ／ 非表示 】

経歴 【 表示 ／ 非表示 】

• 2023年04月

  -

  2025年03月

  医療法人社団　緑成会横浜総合病院, 薬剤部, 薬剤師

• 2025年04月

  -

  継続中

  慶應義塾大学 薬学部, 薬効解析学講座, 助教

学歴 【 表示 ／ 非表示 】

学歴 【 表示 ／ 非表示 】

• 2012年04月

  -

  2019年03月

  慶應義塾大学, 薬学部, 薬学科

  大学, 卒業

• 2019年04月

  -

  2023年03月

  慶應義塾大学大学院

  大学院, 卒業, 博士

学位 【 表示 ／ 非表示 】

学位 【 表示 ／ 非表示 】

• 博士（薬学）, 慶應義塾大学大学院, 課程, 2023年03月

  β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

免許・資格 【 表示 ／ 非表示 】

免許・資格 【 表示 ／ 非表示 】

• 薬剤師免許, 2019年05月

論文 【 表示 ／ 非表示 】

論文 【 表示 ／ 非表示 】

• Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study

  Ishigo T., Suzuki A., Ibe Y., Fujii S., Fukudo M., Yoshida H., Tanaka H., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Samura M., Nagumo F., Komatsu T., Tomizawa A., Takuma A., Chiba H., Nishi Y., Igarashi Y., Enoki Y., Matsumoto K.

  Journal of Antimicrobial Chemotherapy 81 （ 3 ）  2026年03月

  ISSN  03057453

  　概要を見る

  Objectives To clarify the relationship between acute kidney injury (AKI) and vancomycin use in patients with renal impairment and to establish a risk score for AKI. Methods In this retrospective, multicentre, observational cohort study, trough and peak blood samples were collected from patients who initiated vancomycin therapy. The cumulative incidence of AKI within 14 days was compared among three groups classified according to renal function (estimated glomerular filtration rate ≥ 60, 30-59 and <30 mL/min/1.73 m²). The risk score and predicted probability of AKI incidence were calculated. AKI was defined in accordance with the Kidney Disease Improving Global Outcomes criteria. Results The incidence of AKI was 11.7% (99/847). No statistically significant difference was detected in the cumulative incidence of AKI among the three groups (P = 0.103). Cox proportional hazard analysis showed that the use of tazobactam/piperacillin [HR: 3.3, 95% CI (2.18-4.99), 2 points], vasopressors/inotropes [HR: 3.0, 95% CI (2.02-4.51), 2 points] and area under the concentration-time curve (AUC) on Day 2 [500-600 µg·h/mL: HR, 2.4, 95% CI (1.50-3.89), 1 point; >600 µg·h/mL: HR, 4.4, 95% CI (2.62-7.37), 3 points] were significantly related to the development of AKI. The predicted probabilities of AKI incidence were <5% (low-risk), 5% to <20% (moderate-risk), 20% to <40% (high-risk) and 40% to 67% (very high-risk), with total points of 0, 1-2, 3-4 and ≥5, respectively. Conclusions A risk prediction model was developed for AKI based on AUC exposure and concomitant medications, and no difference in AKI risk was observed across renal function categories.

  • Access to Document (DOI)

• Application of epithelial lining fluid drug concentrations to MICi-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia

  Mizukami Y., Takahashi M., Suzuki K., Duan S., Ikegami S., Muraishi T., Satake N., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

  Journal of Infection and Chemotherapy 32 （ 1 ） 102889 2026年01月

  研究論文（学術雑誌）, 責任著者, 査読有り,  ISSN  1341321X

  　概要を見る

  Introduction: Nacubactam is a novel β-lactamase inhibitor with intrinsic antibacterial activity that shows therapeutic potential against carbapenemase-producing Enterobacterales when administered with β-lactam antibiotics. Pharmacokinetics/pharmacodynamics (PK/PD) analyses based on drug concentrations at the site of infection are recommended to better evaluate antibiotic efficacy. A new PD index, the instantaneous minimum inhibitory concentration (MIC<inf>i</inf>), which dynamically reflects the changing susceptibility of β-lactams during co-administration with β-lactamase inhibitors, has recently been proposed. This study aimed to assess the efficacy of cefepime combined with nacubactam in a murine model of pneumonia using MIC<inf>i</inf>-based PK/PD analysis in the lung epithelial lining fluid (ELF). Methods: In vitro pharmacodynamic testing using the checkerboard method was conducted with two β-lactamase-producing Klebsiella pneumoniae strains. In vivo PK and PD studies were performed in neutropenic mice using both β-lactamase-producing and non-producing strains. Drug concentrations in plasma and ELF were measured, and MIC<inf>i</inf>-based PK/PD analysis was conducted. Results: In vitro, the MIC of cefepime decreased in a concentration-dependent manner with increasing nacubactam. In the murine model of pneumonia, cefepime monotherapy resulted in bacterial changes of 0.12–4.30 log<inf>10</inf> CFU/lung, while the combination therapy reduced bacterial counts by −5.93 to −0.234 log<inf>10</inf> CFU/lung. The percentage of time that free cefepime concentrations exceeded MIC<inf>i</inf> (T > MIC<inf>i</inf>) was highly correlated with bacterial reduction. The target T > MIC<inf>i</inf> for maximal effect was estimated to be 29.3 %. Conclusions: These findings support the utility of MIC<inf>i</inf>-based PK/PD analysis for optimizing combination antibiotic therapy in pneumonia.

  • Access to Document (DOI)

• Development and external validation of a population pharmacokinetic model and optimal Vancomycin dosing regimen for overweight and obese patients

  Komatsu T., Tomizawa A., Samura M., Suzuki A., Ishigo T., Fujii S., Ibe Y., Yoshida H., Tanaka H., Fujihara H., Yamaguchi F., Ebihara F., Maruyama T., Yagi Y., Hamada Y., Nagumo F., Takuma A., Chiba H., Nishi Y., Igarashi Y., Enoki Y., Otori K., Matsumoto K.

  Journal of Infection and Chemotherapy 31 （ 12 ） 102838 2025年12月

  研究論文（学術雑誌）, 査読有り,  ISSN  1341321X

  　概要を見る

  Introduction: This study aimed to develop and evaluate a population pharmacokinetic model and optimal dosing regimen for vancomycin in overweight and obese adults. Methods: A population pharmacokinetic model using a two-compartment system was constructed using a nonlinear mixed-effects approach, incorporating 527 data points from 184 participants. External validation of the model was carried out using an additional 55 data points from 21 participants; these were not used in the construction of the model. Monte Carlo simulations were used to determine the dosage that achieved the steady state area under the curve value falling between 400 μg h/mL and 600 μg h/mL. Results: In the final model, vancomycin clearance was found to be a significant predictor of blood vancomycin levels, alongside creatinine clearance (CCr), blood urea nitrogen levels, and incidence of heart failure. CCr was calculated with adjusted body weight (AdjBW). AdjBW was selected as a predictor of the volume of distribution in the central and peripheral compartments. External validation showed that the highest proportion of cases had deviations of less than 15 % between measured and predicted values in the final model developed in this study. This indicates that our model outperforms previously developed models (five for obese patients and four for non-obese patients). Conclusions: Our model shows that determining effective vancomycin doses for overweight and obese patients depend on estimated CCr rates, AdjBW, BUN levels, and incidence of heart failure.

  • Access to Document (DOI)

• Evaluating the necessity of two-point sampling for vancomycin area under the curve in follow-up therapeutic drug monitoring

  Suzuki A., Fujihara H., Yamaguchi F., Yoshida H., Tanaka H., Yagi Y., Maruyama T., Hamada Y., Ishigo T., Fujii S., Nagumo F., Samura M., Chiba H., Ebihara F., Takuma A., Komatsu T., Tomizawa A., Nishi Y., Igarashi Y., Enoki Y., Matsumoto K.

  Journal of Infection and Chemotherapy 31 （ 11 ） 102821 2025年11月

  研究論文（学術雑誌）, 査読有り,  ISSN  1341321X

  　概要を見る

  Objective: While both peak and trough (two-point) sampling are recommended to estimate the area under the concentration-time curve (AUC) for vancomycin, one-point sampling may reduce clinical burden. This study aimed to identify patient populations requiring two-point sampling by examining risk factors associated with AUC discrepancies between one- and two-point sampling during follow-up therapeutic drug monitoring (TDM). Method: This multicenter retrospective observational study included adult patients who received vancomycin from September 2020 to December 2023 and underwent two-point sampling at both initial and follow-up TDM. AUC was estimated using the Practical Antimicrobial TDM (PAT) version 4.0, and creatinine clearance (CLcr) was calculated using the Cockcroft-Gault equation. One- and two-point follow-up AUCs were compared using previously entered two-point concentrations from initial TDM. Patients were divided into a discrepancy group (AUC difference ≥10 %) and a non-discrepancy group. Risk factors were identified by univariate and multivariate analysis. Results: AUC values from one- and two-point sampling in 256 cases were highly correlated (r² = 0.965, p < 0.001). Seventeen cases (6.6 %) showed discrepancies ≥10 %. Multivariate analysis identified BMI ≥25 kg/m² (OR = 6.946, p = 0.001), CLcr <50 mL/min (OR = 5.863, p = 0.002), and ΔCLcr ≥10 mL/min (OR = 4.444, p = 0.012) as significant risk factors. Conclusion: Although one- and two-point AUCs showed strong correlation, discrepancies ≥10 % were more likely in patients with elevated BMI or impaired/unstable renal function. This suggests that two-point sampling may be essential for these patients to ensure accurate dosing of vancomycin during follow-up TDM.

  • Access to Document (DOI)

• Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials

  Kawasaki A., Shintani R., Takao R., Nakazawa Y., Mihara T., Ikegami S., Shimada S., Matsumoto Y., Okamoto Y., Igarashi Y., Enoki Y., Taguchi K., Matsumoto K.

  Medical Mycology （Oxford University Press）  63 （ 10 ） myaf089 2025年09月

  研究論文（学術雑誌）, 共著, 責任著者, 査読有り,  ISSN  13693786

  　概要を見る

  Background Isavuconazole (ISA) is a treatment option for invasive fungal infections (IFIs) and is known for a favorable safety profile compared with other antifungal agents. However, comprehensive evidence regarding its efficacy and safety remains limited. Objectives This study aimed to assess the efficacy and safety of ISA compared with other antifungal agents through a systematic review and meta-analysis restricted to randomized controlled trials (RCTs), to provide more reliable estimates of its clinical effects. Methods Following Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines, a comprehensive literature search was conducted using PubMed, the Cochrane Library, Web of Science, and ClinicalTrials.gov to identify RCTs comparing ISA with other antifungal agents. The primary outcomes were clinical response and mortality. Secondary outcomes included the incidence of adverse events, including serious, drug-related, and organ-specific toxicities. A subgroup analysis was conducted focusing on filamentous fungal infections, comparing ISA and voriconazole. Results Three RCTs met the inclusion criteria. No statistically significant differences were observed between ISA and comparator agents in terms of clinical response, mortality, or total and organ-specific adverse events. A trend toward fewer adverse events was noted in the ISA group. In the subgroup analysis, ISA and voriconazole showed similar efficacy and overall safety; however, the incidence of both drug-related adverse events and hepatobiliary disorders was significantly lower in the ISA group. Conclusions ISA demonstrated efficacy comparable to that of other antifungal agents, with a favorable safety profile in patients with IFIs, including filamentous fungal infections. This meta-analysis of RCTs provides high-quality evidence to support antifungal drug selection in clinical practice.

  • Access to Document (DOI)

全件表示 >>

研究発表 【 表示 ／ 非表示 】

研究発表 【 表示 ／ 非表示 】

• 最小発育阻止濃度未満の濃度による抗菌薬曝露はMycobacterium abscessusのコロニー形態を変化させる

  島村莉奈、西村知泰、吉川万衣子、柏村祥子、矢野大和、三澤可奈、五十嵐裕貴、榎木裕紀、長谷川直樹、南宮湖、松元一明

  [国内会議]  第56回結核・非定型抗酸菌症治療研究会, 

  2026年01月

  , 

  口頭発表（一般）

• 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない

  石郷友之,鈴木絢子,藤居賢,伊部裕太,福土将秀,吉田博昭,田中宏明,海老原文哉,丸山拓実,八木祐助,佐村優,南雲史雄,小松敏彰,冨澤淳,詫間章俊,千葉博暁,五十嵐裕貴,榎木裕紀,浜田幸宏,西圭史,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

  , 

  口頭発表（一般）

• CREによる肺炎マウスモデルを用いたNAC/CFPM併用療法時の目標T＞MICi値

  水上雄貴,岡本侑子,五十嵐裕貴,榎木裕紀,田口和明,池上眞太郎,鈴木健太,高橋実秀,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

• ポサコナゾールの血清タンパク質への結合特性の解析

  岡本侑子,田口和明,五十嵐裕貴,榎木裕紀,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

  , 

  ポスター発表

• バンコマイシンの2回目TDMにおける2点採血の必要性

  鈴木絢子,藤原久登,山口史博,吉田博昭,田中宏明,八木祐助,浜田幸宏,石郷友之,藤居賢,南雲史雄,佐村優,千葉博暁,海老原文哉,丸山拓実,詫間章俊,小松敏彰,冨澤淳,西圭史,五十嵐裕貴,榎木裕紀,松元一明

  [国内会議]  第35回日本医療薬学会年会, 

  2025年11月

  , 

  口頭発表（一般）

全件表示 >>

競争的研究費の研究課題 【 表示 ／ 非表示 】

競争的研究費の研究課題 【 表示 ／ 非表示 】

• 肺オルガノイドと送液灌流系を用いた抗菌薬PK/PD評価モデルの開発

  2026年04月

  -

  2029年03月

  文部科学省・日本学術振興会, 科学研究費助成事業, 若手研究, 補助金,  研究代表者

• Mycobacterium abscessus complexのペニシリン結合タンパク質に対するβ-ラクタム系抗菌薬併用療法の結合特性評価

  2026年03月

  -

  2027年03月

  慶應義塾大学薬学部KP会, KP会星野尚美記念　薬学研究・活動助成金, 補助金,  研究代表者

• MA-T技術を活用した新規消毒剤の開発研究

  2025年08月

  -

  2026年04月

  一般用医薬品セルフメディケーション振興財団, 調査・研究助成, 補助金,  研究代表者

• 瞬間的MICとHFIMを用いた感染部位指向型PK/PD評価手法の構築

  2025年04月

  -

  2027年03月

  文部科学省・日本学術振興会, 科学研究費助成事業, 研究活動スタート支援, 補助金,  研究代表者

• マウス感染モデルを用いた新規β-lactamase阻害薬OP0595のPK/PD評価

  2019年04月

  -

  2020年03月

  慶應義塾大学, 潮田記念基金による博士課程学生研究支援プログラム（研究科推薦枠）, 研究代表者

受賞 【 表示 ／ 非表示 】

受賞 【 表示 ／ 非表示 】

• 第17回日本化学療法学会東日本支部支部長賞（基礎）

  鈴木健太,島村莉奈,吉川万衣子,宇山杏奈,林侑孝,五十嵐裕貴,榎木裕紀,西村知泰,松元一明, 2026年01月, 日本化学療法学会, Hollow Fiber Infection Modelを用いた肺MAC症に対する標準治療の有効性評価

  受賞区分： 国内学会・会議・シンポジウム等の賞

• 第35回日本医療薬学会年会優秀演題賞

  石郷友之,鈴木絢子,藤居賢,伊部裕太,福土将秀,吉田博昭,田中宏明,海老原文哉,丸山拓実,八木祐助,佐村優,南雲史雄,小松敏彰,冨澤淳,詫間章俊,千葉博暁,五十嵐裕貴,榎木裕紀,浜田幸宏,西圭史,松元一明, 2025年11月, 日本医療薬学会, 腎機能低下症例は2点採血でバンコマイシンのAUCを適切に調整することでAKIリスクを上昇させない

  受賞区分： 国内学会・会議・シンポジウム等の賞

• 第8回フレッシャーズ・カンファランス優秀演題発表賞

  島村莉奈,西村知泰,吉川万衣子,三澤可奈,矢野大和,榎木裕紀,五十嵐裕貴,長谷川直樹,南宮湖,松元一明, 2025年06月, 抗菌薬投与が引き起こすMycobacterium abscessusの細胞壁脂質とコロニー形態変化

  受賞区分： 国内学会・会議・シンポジウム等の賞

• 日本化学療法学会Young Challenger Award（YCA）2025

  五十嵐裕貴, 2025年05月, 日本化学療法学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

  受賞区分： 国内学会・会議・シンポジウム等の賞

• 第34回日本医療薬学会年会Postdoctoral award

  五十嵐裕貴, 2024年11月, 日本医療薬学会, β-ラクタム薬/β-ラクタマーゼ阻害薬の併用療法におけるin vivo pharmacokinetics/pharmacodynamics評価方法の構築

  受賞区分： 国内学会・会議・シンポジウム等の賞

全件表示 >>

担当授業科目 【 表示 ／ 非表示 】

担当授業科目 【 表示 ／ 非表示 】

• 課題研究（薬効解析学）

  2025年度

• 演習（薬効解析学）

  2025年度

• 卒業研究１（薬学科）

  2025年度

• 実務実習事前学習（実習）

  2025年度

• 英語演習（薬学科）

  2025年度

全件表示 >>

所属学協会 【 表示 ／ 非表示 】

所属学協会 【 表示 ／ 非表示 】

• 日本病院薬剤師会, 

  2026年02月

  -

  継続中

• 東京都病院薬剤師会, 

  2026年02月

  -

  継続中

• 日本薬学会, 

  2025年11月

  -

  継続中

• 日本臨床薬理学会, 

  2025年01月

  -

  継続中

• 日本医療薬学会, 

  2021年02月

  -

  継続中

全件表示 >>

委員歴 【 表示 ／ 非表示 】

委員歴 【 表示 ／ 非表示 】

• 2025年12月

  -

  継続中

  日本化学療法学会　評議員